Clinical Trial Update: A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine [NA]

View source ↗

Summary

Pilot study evaluating whether the metabolic inhibitor ranolazine can enhance F18 FDG-PET imaging of prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Bone Metastases
• Prostate Cancer

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Adenocarcinoma of the Prostate, Bone Metastases | NA | Status: COMPLETED | Results posted: 2018-06-04